Articles

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Chair of Hematology, “Sapienza” University, Roma, Italy
Hematology Unit, “Pugliese-Ciaccio” Hospital, Catanzaro, Italy
Hematology Unit, “Spedali Civili” Hospital, Brescia, Ravenna, Italy
Chair of Hematology, University of Catania, Ravenna, Italy
Chair of Hematology, University of Udine, Ravenna, Italy
Hematology Unit, “S. Maria delle Croci” Hospital, Ravenna, Italy
Chair of Hematology, Department of Clinical and Biological Sciences, “S. Luigi Gonzaga” University Hospital, University of Torino, Orbassano, Italy
Hematology Unit, “Bianchi-Melacrino-Morelli” Hospital, Reggio Calabria, Italy
Hematology Unit, “S. Giovanni Addolorata” Hospital, Roma, Italy
Chair of Hematology, “S. Maria alle Scotte” Hospital, University of Siena, Piacenza, Italy
Hematology Unit, “Guglielmo da Saliceto” Hospital, Piacenza, Italy
Chair of Hematology, “S. Anna” University Hospital, University of Ferrara, Cagliari, Italy
Hematology Unit, “A. Businco” Hospital, Cagliari, Italy
Chair of Hematology, University of Bari, Napoli, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Chair of Hematology, “Sapienza” University, Roma, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Chair of Hematology, Department of Biochemistry and Medical Biotechnologies, “Federico II” University, Napoli, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Chair of Hematology, Department of Clinical and Biological Sciences, “S. Luigi Gonzaga” University Hospital, University of Torino, Orbassano, Italy
Department of Hematology and Oncology “L. and A. Seràgnoli”, University of Bologna, Italy
Institute of Hematology “L. and A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, “S. Orsola-Malpighi” University Hospital, University of Bologna, Roma, Italy
Vol. 100 No. 9 (2015): September, 2015 https://doi.org/10.3324/haematol.2015.129221